Literature DB >> 15872293

Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus.

Nottasorn Plipat1, Gilat Livni, Heidi Bertram, Richard B Thomson.   

Abstract

We tested 109 unique, vancomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) strains for vancomycin heteroresistance by a selection method, i.e., step-wise exposure of large inoculums to increasing concentrations of vancomycin. Although no strains demonstrated stable heteroresistance, 81 strains (74%) demonstrated unstable heteroresistance. Unstable heteroresistance is common among clinical isolates of MRSA and may represent a cause of therapeutic failure.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15872293      PMCID： PMC1153753          DOI： 10.1128/JCM.43.5.2494-2496.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  The effects of vancomycin and beta-lactam antibiotics on vancomycin-resistant Staphylococcus aureus.

Authors:  I Haraga; S Nomura; A Nagayama
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

2.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

Authors:  K Sieradzki; R B Roberts; S W Haber; A Tomasz
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

3.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

4.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

Review 5.  The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Timothy R Walsh; Robin A Howe
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

6.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

7.  Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Amir Khosrovaneh; Kathleen Riederer; Sajjad Saeed; M Shamse Tabriz; Amar R Shah; Michel M Hanna; Mamta Sharma; Leonard B Johnson; Mohammad G Fakih; Riad Khatib
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

8.  Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.

Authors:  Farid M Hussain; Susan Boyle-Vavra; Priya B Shete; Robert S Daum
Journal:  J Infect Dis       Date:  2002-08-01       Impact factor: 5.226

Review 9.  Glycopeptide resistance in Staphylococcus aureus: is it a real threat?

Authors:  Curtis G Gemmell
Journal:  J Infect Chemother       Date:  2004-04       Impact factor: 2.211

Review 10.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.

Authors:  F C Tenover; J W Biddle; M V Lancaster
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883
View more
  11 in total

1.  In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.

Authors:  Sachin S Bhagwat; Pamela McGhee; Klaudia Kosowska-Shick; Mahesh V Patel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

Review 2.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

3.  Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.

Authors:  Jasmine Chong; Caroline Quach; Ana C Blanchard; Philippe Guillaume Poliquin; George R Golding; Céline Laferrière; Simon Lévesque
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis.

Authors:  Z A Kanafani; W M Kourany; V G Fowler; D P Levine; G A Vigliani; M Campion; D E Katz; G R Corey; H W Boucher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12       Impact factor: 3.267

5.  Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.

Authors:  Adam M Pitz; Fang Yu; Elizabeth D Hermsen; Mark E Rupp; Paul D Fey; Keith M Olsen
Journal:  J Clin Microbiol       Date:  2010-10-20       Impact factor: 5.948

6.  Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.

Authors:  Heather J Adam; Lisa Louie; Christine Watt; Denise Gravel; Elizabeth Bryce; Mark Loeb; Anne Matlow; Allison McGeer; Michael R Mulvey; Andrew E Simor
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

7.  Failure of the MicroScan WalkAway system to detect heteroresistance to carbapenems in a patient with Enterobacter aerogenes bacteremia.

Authors:  N C Gordon; D W Wareham
Journal:  J Clin Microbiol       Date:  2009-07-29       Impact factor: 5.948

Review 8.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

9.  Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.

Authors:  Adina C Musta; Kathleen Riederer; Stephen Shemes; Patrick Chase; Jinson Jose; Leonard B Johnson; Riad Khatib
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948

Review 10.  Mechanisms and clinical relevance of bacterial heteroresistance.

Authors:  Dan I Andersson; Hervé Nicoloff; Karin Hjort
Journal:  Nat Rev Microbiol       Date:  2019-06-24       Impact factor: 60.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.